Block Listing Six Monthly Return

May 16, 2022

16 May 2022

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 

Name of applicant: LungLife AI, Inc.
Name of scheme: 1.       2010 Stock Incentive Plan

2.       2020 Stock Incentive Plan

3.       2021 Omnibus Long-Term Incentive Plan

Number and class of securities originally admitted: 1,356,139 common shares of US $0.0001 each
Date of admission: 15 November 2021
Period of return: From: 15 November 2021 To: 15 May 2022
Balance of unallotted securities under scheme(s) from previous return: 1.       480,775

2.       201,374

3.       673,990

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 1.       NIL

2.       NIL

3.       NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 1.       NIL

2.       NIL

3.       NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1.       480,775

2.       201,374

3.       673,990

Total number of securities in issue at the end of the period 25,480,790

 

Name of contact: David Anderson, Chief Financial Officer
Telephone number of contact: +44 (0)20 7933 8780 or lunglifeai@walbrookpr.com

 

For the full announcement click HERE.

Subscribe for Email Alerts

This field is for validation purposes and should be left unchanged.

© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down